Maravai LifeSciences Holdings, Inc. (MRVI) FY2026 Q2 P&L / Income Statement

Maravai LifeSciences Holdings, Inc. (MRVI) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

51,442,000 US dollars

Cost of revenue

30,792,000 US dollars

Gross profit

20,650,000 US dollars

Operating expenses (calculated)

35,739,000 US dollars

Loss from operations

negative 15,089,000 US dollars

Other income (expense), net (calculated)

negative 6,713,000 US dollars

Loss before income taxes

negative 21,802,000 US dollars

Income tax benefit

negative 171,000 US dollars

Net loss

negative 21,631,000 US dollars

Cygnus - Latin and Central America

193,000 US dollars

Cygnus - Asia Pacific

5,618,000 US dollars

Cygnus - North America

6,638,000 US dollars

Cygnus - Europe, the Middle East and Africa

4,324,000 US dollars

TriLink - Latin and Central America

193,000 US dollars

TriLink - Asia Pacific

3,701,000 US dollars

TriLink - North America

24,646,000 US dollars

TriLink - Europe, the Middle East and Africa

6,129,000 US dollars

Selling, general and administrative

32,070,000 US dollars

Research and development

3,702,000 US dollars

Goodwill impairment

0 US dollars

Restructuring

negative 33,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Maravai LifeSciences Holdings, Inc.: −$12.42 M; to noncontrolling interests: −$9.22 M.